हिंदी में पढ़ें —JantaScope हिंदी
STARTUP NEWS

Aignosis Raises ₹4 Crore to Scale AI-Assisted Autism Screening Across India

Indian healthtech startup Aignosis has raised ₹4 crore in seed funding to expand its AI-assisted autism and developmental screening technology. The company plans to broaden its presence across public health centres, paediatric clinics and schools while targeting at least 100,000 screenings by the end of FY27.

Aignosis Raises ₹4 Crore to Scale AI-Assisted Autism Screening Across India

By Jeet Nirmal

Source: Based on Aignosis' funding announcement and reporting by ETEntrepreneur, with product information cross-checked against Aignosis' official screening materials.

Aignosis Secures ₹4 Crore Seed Funding

Healthtech startup Aignosis has raised ₹4 crore in a seed funding round as it prepares to expand its artificial intelligence-assisted autism and developmental screening platform across India's healthcare ecosystem.

The round included participation from Antler, entrepreneur and investor Nikhil Kamath, Varun Dua and IIMA Ventures.

The new capital marks a shift for the startup from developing and validating its technology toward deploying it more widely across healthcare settings.

Aignosis co-founder Raksheet Jain said the company's next phase will focus on improving access to autism screening, strengthening referral pathways and building a model that can operate across both public and private healthcare systems.

How Aignosis' AI-Assisted Screening Works

Aignosis has developed a screening system intended for children between 16 months and nine years of age.

The system uses equipment that is already widely available — a standard laptop and webcam.

During a screening session, a child watches content organised around nine stimulus modules. Computer-vision technology then evaluates behavioural signals including gaze patterns, response to their name and reactions to facial expressions.

The system generates a risk report indicating whether further clinical assessment may be appropriate.

An important distinction is that the Aignosis screening does not itself diagnose autism.

Aignosis describes its technology as an initial screening layer. Its own reports state that the system is designed to identify potential developmental risks and should not replace a comprehensive clinical evaluation by qualified healthcare professionals.

Why the Screening-versus-Diagnosis Distinction Matters

The difference between screening and diagnosis is particularly important when artificial intelligence is used in healthcare.

A screening system can help identify children who may benefit from further evaluation, potentially allowing healthcare providers to prioritise referrals and reach families earlier.

A clinical diagnosis, however, requires professional evaluation and consideration of a much broader range of information.

Aignosis' model therefore positions AI as an assistive first-stage tool, rather than a substitute for developmental paediatricians, psychologists or other qualified professionals.

That distinction will remain important as the company attempts to deploy its technology across a larger and more diverse population.

Technology Receives CDSCO Class B Certification

According to the company's funding announcement, Aignosis has completed the relevant regulatory process with India's Central Drugs Standard Control Organisation (CDSCO) and received Class B certification for its screening technology.

The startup has also been incubated by IIM Ahmedabad Ventures and was selected for the Google for Startups Accelerator: AI First 2025 cohort.

These milestones have accompanied the company's move from product development toward broader commercial and public-health deployment.

More Than 8,000 Screenings Completed

Aignosis says it has already conducted more than 8,000 screenings.

Its technology has been deployed at more than 20 government primary health centres in Rajasthan, providing an early test of how AI-assisted developmental screening could operate outside major private hospitals.

The startup primarily follows a clinic-in-clinic model.

Instead of relying solely on a standalone consumer product, Aignosis equips paediatricians and healthcare facilities to incorporate developmental screening into their existing clinical workflows.

This distribution strategy could be significant in India, where access to specialised developmental assessment can vary considerably between major cities and smaller communities.

Partnerships With Mankind Pharma and Apollo Shines

Aignosis is also using partnerships to increase the reach of its screening programme.

The startup has partnered with Mankind Pharma, whose network of nearly 1,300 medical representatives is supporting screening camps involving paediatricians across the country.

Aignosis is also beginning operations with Apollo Shines, the Apollo Group's school-infirmary network, across approximately 125 schools.

Together, these channels potentially give the startup access to children through clinics, government health facilities and schools rather than requiring families to independently seek out specialised screening centres.

Targeting 100,000 Screenings by End of FY27

Aignosis has set an ambitious expansion target following the funding round.

After completing more than 8,000 screenings, the company is aiming for at least 100,000 screenings by the end of FY27.

Its geographic expansion plans include Punjab, the National Capital Region, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra.

The company intends to use its experience working in Rajasthan as a reference point for broader adoption, including potential expansion within government healthcare systems.

Why the Funding Matters

The significance of the ₹4 crore round lies not only in the amount raised but in the healthcare problem Aignosis is attempting to address.

Developmental screening can serve as an early gateway to specialist evaluation and support. A technology that works with common hardware such as laptops and webcams could potentially lower infrastructure barriers to providing initial screening in clinics and public-health settings.

AI may also help standardise parts of the initial observation process and allow healthcare providers to screen larger numbers of children.

However, scaling such technology introduces important questions.

Performance must remain reliable across children of different ages, backgrounds and environments. Healthcare providers also need clear procedures for interpreting risk reports and referring children for appropriate clinical evaluation.

Privacy and responsible handling of children's behavioural and health-related data are additional considerations as deployment expands.

AI Could Expand Screening, but Clinical Oversight Remains Essential

Aignosis represents a broader trend in Indian healthtech: using artificial intelligence not necessarily to replace clinicians, but to extend the reach of healthcare services.

If AI-assisted tools can help paediatricians identify developmental concerns earlier, they could become useful components of healthcare systems where specialist resources are limited.

But their value ultimately depends on more than technological performance.

Screening needs to connect children and families with qualified professionals, appropriate diagnostic evaluation and subsequent support when required.

Aignosis' expansion from thousands to a targeted 100,000 screenings will therefore test both the scalability of its technology and its ability to integrate AI screening responsibly into real-world healthcare pathways.

Balanced Analysis

The ₹4 crore funding gives Aignosis additional resources to expand a technology that addresses a meaningful healthcare-access challenge.

Its use of ordinary laptops and webcams, combined with partnerships spanning government health centres, paediatricians and schools, could help make initial developmental screening available in locations where specialist services are harder to access.

At the same time, large-scale deployment of AI in child developmental screening requires careful clinical validation, appropriate professional oversight and clear communication with parents about what a screening result does — and does not — mean.

The company's next phase will therefore be measured not simply by the number of screenings completed, but by how effectively those screenings connect children who may need further evaluation with qualified clinical care.

Related

More stories

Kuku Technologies Turns Profitable as FY26 Revenue Surges More Than Sixfold to ₹1,484 Crore

Digital entertainment company Kuku Technologies, which operates Kuku FM and Kuku TV, swung to profitability in FY26 as operating revenue climbed to ₹1,484.2 crore. The sharp expansion comes as the company scales its microdrama business and prepares for a proposed stock-market listing.

STARTUP NEWS

Kuku Technologies Turns Profitable as FY26 Revenue Surges More Than Sixfold to ₹1,484 Crore

Agrani Labs in Talks to Raise ₹800–850 Crore as Samsung, 360 ONE and Peak XV Eye AI Chip Startup

Bengaluru-based semiconductor startup Agrani Labs is in discussions to raise ₹800–850 crore in a new funding round, with Samsung, 360 ONE Asset Management and existing investor Peak XV Partners among the potential participants, according to people familiar with the talks cited by The Economic Times. The company is also considering ₹120–130 crore in support under the government-backed Research, Development and Innovation scheme. The transaction has not yet been announced as completed.

STARTUP NEWS

Agrani Labs in Talks to Raise ₹800–850 Crore as Samsung, 360 ONE and Peak XV Eye AI Chip Startup

Indian Space Startups Send Multiple Payloads Into Orbit Aboard SpaceX Falcon 9

Indian space startups have successfully sent multiple satellites and technology payloads into orbit aboard SpaceX's Falcon 9 on the Transporter-18 rideshare mission, demonstrating capabilities ranging from thermal Earth observation and compact optical imaging to artificial intelligence-powered computing in space.

STARTUP NEWS

Indian Space Startups Send Multiple Payloads Into Orbit Aboard SpaceX Falcon 9

Former Elevation Capital Partner Mayank Khanduja Joins Bessemer Venture Partners in India

Veteran venture capitalist Mayank Khanduja has joined Bessemer Venture Partners as a partner in its India practice after a nearly 15-year stint at Elevation Capital. Based in Bengaluru, Khanduja will focus on early-stage investments across sectors including consumer technology, gaming, healthcare, artificial intelligence and deeptech.

STARTUP NEWS

Former Elevation Capital Partner Mayank Khanduja Joins Bessemer Venture Partners in India

Google Unveils Gemini 4 Argon, Its Most Advanced AI Model Yet

Google has unveiled Gemini 4 Argon, its new frontier artificial intelligence model designed for complex coding, enterprise knowledge work and cybersecurity defense. The model introduces significantly expanded capacity for long-running tasks, but Google is taking a controlled approach to availability, initially providing access to selected cybersecurity partners.

STARTUP NEWS

Google Unveils Gemini 4 Argon, Its Most Advanced AI Model Yet

Bharat Housing Network Raises $5 Million From Symbiotics to Expand Green Financing

Bharat Housing Network (BHN) has raised $5 million, or roughly ₹47 crore, through green bonds from Symbiotics, with the capital earmarked for rooftop solar, electric mobility and clean-tech MSME financing in India. The transaction is part of a broader $75 million green bond programme involving Symbiotics and British International Investment.

STARTUP NEWS

Bharat Housing Network Raises $5 Million From Symbiotics to Expand Green Financing